Rubric Capital Management LP Viracta Therapeutics, Inc. Transaction History

Rubric Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.38 - $2.29 $215,834 - $358,160	156,402 Added 11.75%	1,487,385 $2.36 Million
Q4 2022 Feb 10, 2023	BUY	$1.26 - $4.38 $423,589 - $1.47 Million	336,182 Added 33.79%	1,330,983 $1.94 Million
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $3.3 Million - $5.66 Million	994,801 New	994,801 $4.25 Million

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.